Tandem Diabetes Care Inc (TNDM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Tandem Diabetes Care Inc stock (TNDM) is currently trading at $24.51. Tandem Diabetes Care Inc PS ratio (Price-to-Sales) is 1.67. Analyst consensus price target for TNDM is $30.50. WallStSmart rates TNDM as Sell.
- TNDM PE ratio analysis and historical PE chart
- TNDM PS ratio (Price-to-Sales) history and trend
- TNDM intrinsic value — DCF, Graham Number, EPV models
- TNDM stock price prediction 2025 2026 2027 2028 2029 2030
- TNDM fair value vs current price
- TNDM insider transactions and insider buying
- Is TNDM undervalued or overvalued?
- Tandem Diabetes Care Inc financial analysis — revenue, earnings, cash flow
- TNDM Piotroski F-Score and Altman Z-Score
- TNDM analyst price target and Smart Rating
Tandem Diabetes Care Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Tandem Diabetes Care Inc (TNDM) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Tandem Diabetes Care Inc (TNDM) Key Strengths (2)
112.74% of shares held by major funds and institutions
Paying $1.67 for every $1 of annual revenue
Supporting Valuation Data
Tandem Diabetes Care Inc (TNDM) Areas to Watch (7)
Company is destroying shareholder value
Earnings declining -37.00%, profits shrinking
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very expensive at 10.9x book value
Revenue growing slowly at 2.70% annually
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Tandem Diabetes Care Inc (TNDM) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales. Valuation metrics including Price/Sales (1.67) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Some valuation metrics including Price/Book (10.93) suggest expensive pricing. Growth concerns include Revenue Growth at 2.70%, EPS Growth at -37.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -97.90%, Operating Margin at 2.86%, Profit Margin at -20.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -97.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TNDM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TNDM's Price-to-Sales ratio of 1.67x trades at a deep discount to its historical average of 19.78x (16th percentile). The current valuation is 100% below its historical high of 684.68x set in Dec 2013, and 289% above its historical low of 0.43x in Jul 2017. Over the past 12 months, the PS ratio has expanded from ~1.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Tandem Diabetes Care Inc (TNDM) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Tandem Diabetes Care Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 1.0B with 3% growth year-over-year. The company is currently unprofitable, posting a -20.2% profit margin.
Key Findings
Generating 3M in free cash flow and 10M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -20.2% profit margin. The path to breakeven will be the key catalyst.
Debt-to-equity ratio of 3.64 is elevated. High leverage amplifies both gains and losses and increases financial risk.
What to Watch Next
Volatility is elevated with a beta of 1.67, so expect amplified moves relative to the broader market.
Debt management: total debt of 564M is significantly higher than cash (91M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Tandem Diabetes Care Inc.
Bottom Line
Tandem Diabetes Care Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(50 last 3 months)
| Insider | Type | Shares |
|---|---|---|
NOVARA, MARK DAVID EVP & CHIEF COMMERCIAL OFFICER | Sell | -187 |
| Insider | Type | Shares |
|---|---|---|
NOVARA, MARK DAVID EVP & CHIEF COMMERCIAL OFFICER | Sell | -2 |
Data sourced from SEC Form 4 filings
Last updated: 10:09:54 AM
About Tandem Diabetes Care Inc(TNDM)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.